FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1489663513> ?p ?o ?g. }

• W1489663513 endingPage "2314" @default.
• W1489663513 startingPage "2302" @default.
• W1489663513 abstract "// Xiaodong He 1,* , Jingjing Li 1,* , Weidong Guo 2,* , Wei Liu 1 , Jia Yu 3 , Wei Song 3 , Lei Dong 3 , Fang Wang 3 , Shuangni Yu 4 , Yi Zheng 1 , Songsen Chen 3 , Yan Kong 5 and Changzheng Liu 3 1 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, PR China 2 Department of Hepatobiliary Surgery, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, PR China 3 Department of Biochemistry and Molecular Biology, State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, PR China 4 Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, PR China 5 Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China * Authors share co-first authorship Correspondence: Changzheng Liu, email: // Yan Kong, email: // Wei Liu, email: // Keywords : microRNA-21, AP-1, hepatocellular carcinoma, chemotherapy, HIAC Received : September 30, 2014 Accepted : December 09, 2014 Published : December 10, 2014 Abstract MicroRNAs function as oncomiRs and tumor suppressors in diverse cancers. However, the utility of specific microRNAs in predicting the clinical benefit of chemotherapy has not been well-established. Here, we investigated the correlation between microRNA-21 expression and hepatic arterial infusion chemotherapy with 5-fluorouracil and pirarubicin (HAIC) for hepatocellular carcinoma (HCC). We found that HCC patients with low microRNA-21 levels in tumors tended to have a longer time to recurrence and disease-free survival. We demonstrated that microRNA-21 suppression in combination with 5-fluorouracil and pirarubicin treatment inhibited tumor growth in subcutaneous xenograft mice models. Mechanistically, the AP-1 and microRNA-21-mediated axis was verified to be a therapeutic target of cytotoxic drugs and deregulation of this axis led to an enhanced cell growth in HCC. Taken together, our findings demonstrate that microRNA-21 is a chemotherapy responsive microRNA and can serve as a prognostic biomarker for HCC patients undergoing HAIC. Targeting microRNA-21 enhances the effect of chemotherapeutic drugs, thereby suggesting that microRNA-21 suppression in combination with HAIC may be a novel approach for HCC treatment." @default.
• W1489663513 created "2016-06-24" @default.
• W1489663513 creator A5002661071 @default.
• W1489663513 creator A5003275608 @default.
• W1489663513 creator A5006367043 @default.
• W1489663513 creator A5008711275 @default.
• W1489663513 creator A5009562986 @default.
• W1489663513 creator A5013617878 @default.
• W1489663513 creator A5018635864 @default.
• W1489663513 creator A5034416053 @default.
• W1489663513 creator A5050749770 @default.
• W1489663513 creator A5054028325 @default.
• W1489663513 creator A5055356574 @default.
• W1489663513 creator A5063195311 @default.
• W1489663513 creator A5070745113 @default.
• W1489663513 date "2014-12-10" @default.
• W1489663513 modified "2023-09-25" @default.
• W1489663513 title "Targeting the microRNA-21/AP1 axis by 5-fluorouracil and pirarubicin in human hepatocellular carcinoma" @default.
• W1489663513 cites W1902459366 @default.
• W1489663513 cites W1975154077 @default.
• W1489663513 cites W1980718338 @default.
• W1489663513 cites W1981989535 @default.
• W1489663513 cites W1986630370 @default.
• W1489663513 cites W1989941644 @default.
• W1489663513 cites W1995418633 @default.
• W1489663513 cites W2000093333 @default.
• W1489663513 cites W2002207325 @default.
• W1489663513 cites W2010609260 @default.
• W1489663513 cites W2029426792 @default.
• W1489663513 cites W2038066298 @default.
• W1489663513 cites W2051678809 @default.
• W1489663513 cites W2075715091 @default.
• W1489663513 cites W2079997492 @default.
• W1489663513 cites W2080029244 @default.
• W1489663513 cites W2084795153 @default.
• W1489663513 cites W2087837402 @default.
• W1489663513 cites W2088629624 @default.
• W1489663513 cites W2092400840 @default.
• W1489663513 cites W2094991927 @default.
• W1489663513 cites W2099749771 @default.
• W1489663513 cites W2105493915 @default.
• W1489663513 cites W2105901093 @default.
• W1489663513 cites W2106787323 @default.
• W1489663513 cites W2107515690 @default.
• W1489663513 cites W2117362596 @default.
• W1489663513 cites W2123218517 @default.
• W1489663513 cites W2136364303 @default.
• W1489663513 cites W2149771650 @default.
• W1489663513 cites W2157702264 @default.
• W1489663513 cites W2159209399 @default.
• W1489663513 cites W2159807040 @default.
• W1489663513 cites W2161163389 @default.
• W1489663513 cites W2161994180 @default.
• W1489663513 cites W2166310425 @default.
• W1489663513 cites W2166906519 @default.
• W1489663513 cites W2169545259 @default.
• W1489663513 cites W2322523258 @default.
• W1489663513 cites W2325700417 @default.
• W1489663513 cites W64752819 @default.
• W1489663513 doi "https://doi.org/10.18632/oncotarget.2955" @default.
• W1489663513 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4385853" @default.
• W1489663513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25544773" @default.
• W1489663513 hasPublicationYear "2014" @default.
• W1489663513 type Work @default.
• W1489663513 sameAs 1489663513 @default.
• W1489663513 citedByCount "29" @default.
• W1489663513 countsByYear W14896635132015 @default.
• W1489663513 countsByYear W14896635132016 @default.
• W1489663513 countsByYear W14896635132017 @default.
• W1489663513 countsByYear W14896635132018 @default.
• W1489663513 countsByYear W14896635132019 @default.
• W1489663513 countsByYear W14896635132020 @default.
• W1489663513 countsByYear W14896635132021 @default.
• W1489663513 countsByYear W14896635132022 @default.
• W1489663513 crossrefType "journal-article" @default.
• W1489663513 hasAuthorship W1489663513A5002661071 @default.
• W1489663513 hasAuthorship W1489663513A5003275608 @default.
• W1489663513 hasAuthorship W1489663513A5006367043 @default.
• W1489663513 hasAuthorship W1489663513A5008711275 @default.
• W1489663513 hasAuthorship W1489663513A5009562986 @default.
• W1489663513 hasAuthorship W1489663513A5013617878 @default.
• W1489663513 hasAuthorship W1489663513A5018635864 @default.
• W1489663513 hasAuthorship W1489663513A5034416053 @default.
• W1489663513 hasAuthorship W1489663513A5050749770 @default.
• W1489663513 hasAuthorship W1489663513A5054028325 @default.
• W1489663513 hasAuthorship W1489663513A5055356574 @default.
• W1489663513 hasAuthorship W1489663513A5063195311 @default.
• W1489663513 hasAuthorship W1489663513A5070745113 @default.
• W1489663513 hasBestOaLocation W14896635131 @default.
• W1489663513 hasConcept C104317684 @default.
• W1489663513 hasConcept C126322002 @default.
• W1489663513 hasConcept C142724271 @default.
• W1489663513 hasConcept C143998085 @default.
• W1489663513 hasConcept C145059251 @default.
• W1489663513 hasConcept C17744445 @default.
• W1489663513 hasConcept C188947578 @default.
• W1489663513 hasConcept C191935318 @default.
• W1489663513 hasConcept C199539241 @default.

• next